Prior to joining PROTEINA, Dr. Lee held research roles at Yonsei University and KAIST. Dr. Lee is a co-founder of PROTEINA’s core technology and brings extensive expertise in the field of physics and technology. Dr Lee, has led numerous collaborations with global pharmaceutical companies focused on cancer signaling investigations, and continued to push forward PROTEINA’s technological advances keeping the company at the forefront of innovation. He continues to lead and expand PROTEINA’s many high-performing teams across diverse technical domains.

In 2024, he was honored with the IR52 Jang Young Sil Award for his invention of a therapeutic response prediction method for hematological cancers.